Abstract
Background:
We added panitumumab to standard combination chemotherapy as first-line treatment for patients with advanced KRAS WT non-squamous NSCLC.
Methods:
Patients received panitumumab 9 mg/kg IV, pemetrexed 500 mg/m2 IV, and carboplatin AUC = 6 IV every 21 days. After 6 cycles, maintenance therapy with panitumumab and pemetrexed was administered every 21 days until progressive disease or unacceptable toxicity.
Results:
29 of 66 patients (44%) had objective responses. The median TTP was 6 months; median overall survival (OS) was 17 months. Panitumumab increased treatment-related toxicity, notably skin rash.
Conclusions:
The addition of panitumumab increased toxicity, and had no discernible impact on efficacy.
Keywords:
EGFR inhibitor; KRAS wild-type; NSCLC; Panitumumab.
Publication types
-
Clinical Trial, Phase II
-
Multicenter Study
MeSH terms
-
Aged
-
Aged, 80 and over
-
Antibodies, Monoclonal / administration & dosage*
-
Antibodies, Monoclonal / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Carboplatin / administration & dosage*
-
Carboplatin / adverse effects
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / genetics
-
Carcinoma, Non-Small-Cell Lung / pathology
-
Drug Administration Schedule
-
Female
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / genetics
-
Lung Neoplasms / pathology
-
Male
-
Middle Aged
-
Panitumumab
-
Pemetrexed / administration & dosage*
-
Pemetrexed / adverse effects
-
Proto-Oncogene Proteins p21(ras) / genetics
-
Survival Analysis
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
KRAS protein, human
-
Pemetrexed
-
Panitumumab
-
Carboplatin
-
Proto-Oncogene Proteins p21(ras)